MYC Gene Rearrangements Are Closely Associated with Poor Survival of Diffuse Large B Cell Lymphoma with Hepatitis B Virus Infection

Zhihe Liu,Wei Guo,Siyun Li,Ou Bai,Ming Wang,Yinping Wang

doi:10.1155/2017/1967648

Abstract

The aim of this study was to identify clinical adverse prognostic factors affecting overall survival (OS) of diffuse large B cell (DLBCL) patients with hepatitis B virus (HBV) infection. In this study, 30 DLBCL patients with HBV infection and 51 DLBCL patients with HBV-free were reviewed retrospectively. As of July 2016, the median follow-up period was 26.4 months (3.0~65.0 months). The median OS of patients in HBV infection group was 38.6 months, while that of patients in HBV-free group was not reached (P = 0.042); the median progression-free survival (PFS) of patients in HBV infection group was worse than that in HBV-free group, 18.5 months and 38.5 months (P = 0.118), respectively. The rate of MYC and BCL2 gene rearrangements in HBV infection group was significantly higher than that in HBV-free group, 20.0% versus 3.9% (P = 0.019) and 23.3% versus 5.9% (P = 0.021), respectively. Multivariable analysis indicated that IPI (P = 0.002), chemotherapy regimens (P = 0.017), and MYC gene rearrangements (P = 0.004) were independent adverse prognostic factors for all DLBCL patients in this study. Results demonstrated that the poor survival of DLBCL patients with HBV infection was closely involved in chemotherapy regimens, IPI, and MYC gene rearrangements.

Highlights

hepatitis B virus (HBV) infection remains a serious public health problem
The first patient had HBV reactivation after the fifth cycle of rituximab-containing chemotherapy combined with Lamivudine therapy; the second patient contracted HBV reactivation after the third cycle of chemotherapy without rituximab combined with Lamivudine therapy; the last patient suffered from HBV reactivation after the second cycle of rituximab-containing chemotherapy combined with Lamivudine therapy
We investigated the prognosis and risk factors of diffuse large B cell (DLBCL) patients with HBV infection

Summary

Introduction

HBV infection remains a serious public health problem. It is reported that there are nearly 2 billion people currently suffering from HBV infection, and some 360 million are believed to be infected with chronic HBV infection worldwide, which includes 93 million people in China [1,2,3]. China currently is still a region where HBV is endemic. To the best of our knowledge, the pathogenesis of many diseases is closely associated with HBV infection. It has already been confirmed that HBV infection can remarkably increase the incidence of lymphomas, especially DLBCL [5,6,7]. There are few articles systematically investigating clinical adverse prognostic factors of DLBCL patients with HBV infection. The purpose of this study is to explore clinical adverse prognostic factors of DLBCL patients with HBV infection

Objectives

Methods

Results

Conclusion